Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BGI Genomics Co., Ltd. (300676.SZ)
Shenzhen, CN
BGI Genomics Co., Ltd. operates as an international supplier of genetic testing solutions and sequencing services. The company caters to a broad clientele, encompassing medical and research facilities, as well as other public and private organizations, both within China and across the globe. Its comprehensive service portfolio includes DNA, RNA, and tailored sequencing options. Additionally, it offers a suite of specialized genetic tests such as non-invasive prenatal testing (NIPT), reproductive health screening, and newborn genetic screening, alongside clinical exome sequencing. BGI Genomics also develops clinical and research-focused solutions for the field of oncology. During the COVID-19 pandemic, the firm provided crucial laboratory solutions for the detection and diagnosis of suspected cases, including SARS-CoV-2 IgM and IgG antibody detection kits, and real-time fluorescent RT-PCR kits. Their expertise spans numerous research domains, including but not limited to agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug development. Established in 1999, the company initially operated under the name Shenzhen BGI Medicine Co., Ltd. before officially changing to BGI Genomics Co., Ltd. in 2015. Its corporate headquarters are located in Shenzhen, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46% | -1.79% | -7.89% | -24.28% | -21.14% | -18.89% | -28.45% | -37.80% | -71.40% | +87.32% | +87.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-4.5% Q1'26: +20.4% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+32.4% ★ Q1'26: +82.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-26.3% Q1'26: -41.8% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-15.2% Q1'26: -4.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-10.0% Q1'26: -2.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+1.0% Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×152.48× ★ Q1'26: -5.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.80B
est: 3.42B (-18.1%)
|
8.40B
est: 9.14B (-8.1%)
|
6.77B
est: 6.68B (+1.2%)
|
7.05B
est: 5.83B (+20.9%)
|
4.35B
est: 7.33B (-40.6%)
|
3.87B
est: 3.95B (-2.1%)
|
3.70B
est: 3.60B (+2.5%)
|
3.89B
3.89B – 3.89B
+7.8% YoY
|
4.13B
4.13B – 4.13B
+6.3% YoY
|
4.48B
4.48B – 4.48B
+8.4% YoY
|
| EBITDA |
498.67M
est: 579.18M (-13.9%)
|
2.95B
est: 1.55B (+90.2%)
|
1.96B
est: 1.13B (+73.0%)
|
1.26B
est: 988.56M (+27.7%)
|
482.76M
est: 1.24B (-61.1%)
|
-320.95M
est: 393.42M (-181.6%)
|
5.14M
est: 358.87M (-98.6%)
|
386.85M
386.85M – 386.85M
+7.8% YoY
|
411.24M
411.24M – 411.24M
+6.3% YoY
|
445.70M
445.70M – 445.70M
+8.4% YoY
|
| EBIT |
257.59M
est: 360.20M (-28.5%)
|
2.64B
est: 962.86M (+174.5%)
|
1.68B
est: 704.38M (+138.5%)
|
905.27M
est: 614.80M (+47.2%)
|
112.94M
est: 772.25M (-85.4%)
|
-736.53M
est: 47.39M (-1,654.2%)
|
-562.32M
est: 43.23M (-1,400.8%)
|
46.60M
46.60M – 46.60M
+7.8% YoY
|
49.54M
49.54M – 49.54M
+6.3% YoY
|
53.69M
53.69M – 53.69M
+8.4% YoY
|
| Net Income |
276.33M
est: 569.07M (-51.4%)
|
2.09B
est: 3.58B (-41.5%)
|
1.46B
est: 1.51B (-2.9%)
|
802.77M
est: 1.03B (-22.1%)
|
92.90M
est: 832.98M (-88.8%)
|
-902.69M
est: -857.62M (-5.3%)
|
-616.66M
est: 24.98M (-2,568.7%)
|
70.77M
70.77M – 70.77M
+183.3% YoY
|
66.61M
66.61M – 66.61M
-5.9% YoY
|
137.39M
137.39M – 137.39M
+106.2% YoY
|
| SGA |
803.04M
est: 960.46M (-16.4%)
|
1.61B
est: 2.57B (-37.4%)
|
1.61B
est: 1.88B (-14.0%)
|
1.98B
est: 1.64B (+20.9%)
|
1.43B
est: 2.06B (-30.6%)
|
1.41B
est: 1.24B (+14.0%)
|
1.31B
est: 1.13B (+16.0%)
|
1.22B
1.22B – 1.22B
+7.8% YoY
|
1.30B
1.30B – 1.30B
+6.3% YoY
|
1.40B
1.40B – 1.40B
+8.4% YoY
|
| EPS |
0.69
est: 1.38 (-50.0%)
|
5.25
est: 8.67 (-39.4%)
|
3.56
est: 3.65 (-2.5%)
|
1.96
est: 2.50 (-21.6%)
|
0.23
est: 2.02 (-88.6%)
|
-2.19
est: -2.06 (-6.3%)
|
-1.48
est: 0.06 (-2,566.7%)
|
0.17
0.17 – 0.17
+183.3% YoY
|
0.16
0.16 – 0.16
-5.9% YoY
|
0.33
0.33 – 0.33
+106.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.11% | 39.5K | 0.65% |
| 2 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.03% | 4.6K | 0.65% |
| 3 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.6K | 0.15% |
| 4 | State Street SPDR S&P China ETF GXC | 0.01% | 46.1K | 0.59% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 50.2K | 0.46% |
| 6 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 84.6K | 0.17% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 84.6K | 0.17% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 17.0K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 38.4K | 0.26% |
| 10 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 152.3K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao Li | Deputy GM and Head of Marketing Center & i99 Division | — | male |
| Hui Liu | Head of the accounting department & Accounting Supervisor | — | — |
| Qian Xu | Director of Legal Affairs, General Counsel, Deputy GM & Secretary | — | female |
| Shida Zhu | Deputy GM & Non Independent Director | — | male |
| Weijun Chen | Deputy General Manager | — | male |
| Yong Hou | General Manager | — | male |
| Yujue Wang | Chief Financial Officer, Deputy GM & Non Independent Director | — | male |
| Yun Yang | VP & Head of Product Center | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300676.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
